We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

3 hedge funds and large institutions have $6.79M invested in Hepion Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more capital invested

Capital invested by funds: $4.44M → $6.79M (+$2.35M)

0% more funds holding

Funds holding: 3 → 3 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TA
Teachers Advisors
New York
+$559K
2
TCIM
TIAA CREF Investment Management
New York
+$559K

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$1.37M
2
Goldman Sachs
Goldman Sachs
New York
-$14K
3
BIM
BlackRock Investment Management
Delaware
-$6K
4
Creative Planning
Creative Planning
Kansas
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Creative Planning
26
Creative Planning
Kansas
– -$1K – –
Goldman Sachs
27
Goldman Sachs
New York
– -$14K – –
1
2

HEPA Hedge Fund Activity: Q2 2016 in Review

3 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q2 2016, worth a combined $6.79M — up 53% from $4.44M a quarter earlier.

Fund positioning in HEPA was balanced in Q2 2016: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Teachers Advisors, opening a new position worth an estimated $559K. The largest seller was Anson Funds Management, exiting entirely with an estimated $1.37M sold.

  • 3 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q2 2016, unchanged from Q1 2016.
  • Funds reported $6.79M of Hepion Pharmaceuticals stock for Q2 2016, up 53% quarter-over-quarter.
  • 1 fund opened new Hepion Pharmaceuticals positions in Q2 2016 and 1 closed out, a net change of 0 holders.
  • The largest Hepion Pharmaceuticals buyer in Q2 2016 was Teachers Advisors, an estimated $559K added.
  • The largest Hepion Pharmaceuticals seller in Q2 2016 was Anson Funds Management, an estimated $1.37M sold.

Based on aggregated 13F filings for Q2 2016.